Longevium raises $7M for Dubai longevity research lab

Longevium, a UAE-based health technology company, has closed a $7 million debut funding round. The money will pay for a new research laboratory at Dubai Science Park, a project led by the company's founder, Dr Ksenia Butova. Construction is underway, and the facility is expected to open in the fourth quarter of 2026.

This is not a clinic. The Longevity AI Research Laboratory will operate as a dedicated research and development centre, producing data, algorithms, and prototypes rather than seeing patients. Its mission is to develop technologies that predict health risks, measure biological ageing, and help people maintain healthier lifespans.

The laboratory's method is interdisciplinary. It will draw on artificial intelligence, biomedical research, and clinical expertise, using them together rather than in isolation. The goal is to close the gap between laboratory findings and practical preventive care.

Dubai has made longevity science a government priority. The recently created Dubai Longevity Authority is the institutional expression of that ambition. Longevium's laboratory is designed to align with the authority's work and to reinforce the emirate's position as a hub for longevity medicine.

The $7 million will finance the laboratory itself and support research into next-generation diagnostics, longevity technologies, and clinical research programmes. One of the most prominent strands is the development of AI-powered digital twins.

A digital twin is a virtual replica of a patient. Physicians would use it to simulate different treatment protocols before applying any of them in practice. That allows doctors to test personalised approaches cheaply and safely, without putting the patient at risk.

Regenerative medicine is another focus. The lab will investigate tissue engineering and advanced cell therapies, both aimed at restoring organ function. These are early-stage fields, but the potential payoff is large.

Robotic diagnostics feature heavily in the research agenda. The laboratory will explore swallowable imaging capsules, which are small cameras a patient can ingest. It will also look at AI-based skin cancer scanners and smart contact lenses capable of monitoring health through analysis of tear fluid.

A less familiar line of research concerns noble gas therapy. Xenon, argon, helium, and krypton are all under investigation. The laboratory will study their potential in organ protection, stress-related conditions, and neurodegenerative diseases.

The approach is explicitly about prevention. The technologies under development are meant to catch health problems early, measure how the body is ageing, and support longer, healthier lives. None of that has reached clinical practice yet.

These are early-stage inquiries. The laboratory is being built as a research hub, not a treatment facility. Whether these technologies reach clinical practice will depend on years of work to come.